Nintedanib Slows Rate of FVC Decline in Fibrosing Interstitial Lung Diseases
Treatment with nintedanib was associated with slowing the rate of forced vital capacity decline in patients with progressive fibrosing interstitial lung diseases.
Treatment with nintedanib was associated with slowing the rate of forced vital capacity decline in patients with progressive fibrosing interstitial lung diseases.
Patients with sleep apnea who received positive airway pressure therapy did not exhibit reduced cardiovascular risk compared with patients who received usual care.
High quality communication in tobacco treatment programs with lung cancer screenings was significantly associated with self-efficacy for smoking cessation.
The MuLBSTA score accurately predicted outcomes of hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia.
Researchers examined patients with central sleep apnea after 5 years of treatment with transvenous phrenic nerve stimulation therapy.
Among lung transplant recipients, tacrolimus compared to cyclosporine may be associated with decreased incidence of bronchiolitis obliterans syndrome and number of acute rejection episodes.
In patients with sarcoidosis, cancer was found to develop earlier in men vs women.
In patients with type 2 asthma, dupilumab was associated with significantly lower annualized outpatient asthma exacerbation rates and lower total number of days using systemic corticosteroids.
Patients with acute respiratory distress syndrome and a preexisting psychiatric illness, particularly generalized anxiety disorder, were more likely to develop intensive care unit delirium.